Will Medicare Cover Ozempic? What Retirees Should Know About GLP-1 Coverage
GLP-1 drugs like Ozempic and Wegovy are changing the cost landscape for retirees. This guide breaks down what Medicar...
GLP-1
This tag page compiles 4 articles on GLP-1 trends, pricing, and weight-loss stock impacts, helping you understand how drug costs and market moves affect personal finances.
10 articles
Forget Oral Wegovy: This Could Be a Bigger Win for Investors
The launch of oral Wegovy marked a turning point for weight-loss drugs and stock investors. But a newer, rival oral G...
Lilly Falls on Oral Obesity Pill as FDA Decision Looms
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Is There Much Bullishness Priced Into Eli Lilly Stock?
Eli Lilly has enjoyed rapid growth from GLP-1 drugs, but sky-high expectations invite questions about valuations. Thi...
Lilly Just Opened Door to a GLP-1 Growth Boom in Markets
Eli Lilly unveiled a direct-to-employer program for Zepbound, aiming to accelerate GLP-1 adoption and expand market s...
Health Startup Noom Adding GLP-1 Drugs to Med Plan Now
Noom is shifting from psychology-based weight loss to prescription treatments, launching Noom Med in a multi-state ro...
Novo Nordisk Slashing Prices Could Boost the Stock
Novo Nordisk slashing prices is drawing attention from investors who wonder how a price cut could actually lift the s...
Better Weight Loss Stock: Novo Nordisk vs Amgen Showdown
The weight loss field is heating up, with Novo Nordisk leading the GLP-1 wave and Amgen pursuing a smaller, more sele...
Forget Ozempic: This High-Flying Device Maker Stands Strong
In a world obsessed with weight-loss drugs, a different growth engine quietly powers ahead. This article explains why...
Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...